Rakesh Soni - Net Worth and Insider Trading

Rakesh Soni Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Rakesh Soni owns 2 companies in total, including Rexahn Pharmaceuticals Inc (REXN) , and Ocuphire Pharma Inc (OCUP) .

Click here to see the complete history of Rakesh Soni’s form 4 insider trades.

Insider Ownership Summary of Rakesh Soni

Ticker Comapny Transaction Date Type of Owner
REXN Rexahn Pharmaceuticals Inc 2014-01-12 President and COO
OCUP Ocuphire Pharma Inc 2008-07-14 Chief Business Officer

Rakesh Soni Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Rakesh Soni Ownership Network

Ownership Network List of Rakesh Soni

No Data

Ownership Network Relation of Rakesh Soni

Insider Network Chart

Rakesh Soni Owned Company Details

What does Rexahn Pharmaceuticals Inc do?

Who are the key executives at Rexahn Pharmaceuticals Inc?

Rakesh Soni is the President and COO of Rexahn Pharmaceuticals Inc. Other key executives at Rexahn Pharmaceuticals Inc include Chief Medical Officer Ely Benaim , Chief Business Officer Lisa Nolan , and director & President and CEO Douglas J Swirsky .

Rexahn Pharmaceuticals Inc (REXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rexahn Pharmaceuticals Inc (REXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rexahn Pharmaceuticals Inc (REXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rexahn Pharmaceuticals Inc (REXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Rexahn Pharmaceuticals Inc Insider Transactions

No Available Data

Rakesh Soni Mailing Address

Above is the net worth, insider trading, and ownership report for Rakesh Soni. You might contact Rakesh Soni via mailing address: 9620 Medical Center Drive, Rockville Md 20850.

Discussions on Rakesh Soni

No discussions yet.